CLINICAL_TRIALS
trial_result
· 2020-12-11
Clinical Trial Update: Efficacy and Safety of CD5024 1% in Acne Vulgaris [Phase 2]
Summary
A Phase 2 trial assessing the efficacy and safety of CD5024 1% in acne vulgaris has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Galderma R&D | Conditions: Acne | Phase 2 | Status: COMPLETED | Results posted: 2020-12-11